

---

## THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

---

If you are in any doubt about any aspect of this circular, you should obtain independent professional advice.

If you have sold or transferred all your H Shares in **Sinopharm Group Co. Ltd.**, you should at once hand this circular together with the form of proxy to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*

**(Stock Code: 01099)**

- (1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS;  
(2) PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS; AND  
(3) NOTICE OF EGM**
- 

A letter from the Board is set out on pages 3 to 7 of this circular. A notice convening the EGM to be held at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC, at 9:00 a.m. on Friday, 15 September 2023, is being dispatched to the Shareholders together with this circular.

Shareholders who intend to appoint a proxy to attend the EGM shall complete and return the appropriate proxy form in accordance with the instructions printed thereon. The proxy form must be signed by you or your attorney duly authorized in writing or, in case of a legal person, must either be executed under its seal or under the hand of its director or other attorney duly authorized to sign the same. If the proxy form is signed by an attorney of the appointor, the power of attorney authorizing the attorney to sign, or other document of authorization, must be notarially certified.

In the case of joint holders of the shares of the Company, only the holder whose name stands first in the register of members of the Company shall alone be entitled to vote at the EGM, either in person or by proxy in respect of such shares.

For holders of H Shares, please return the proxy form together with any documents of authority to the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible, and in any event not later than 24 hours before the time appointed for holding the EGM or any adjournment thereof. For holders of Domestic Shares, please return the proxy form together with any documents of authority to the Board Office of the Company in the PRC at Room 1210, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC as soon as possible, and in any event not later than 24 hours before the time appointed for holding the EGM or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting at the EGM, or any adjournment thereof should you so wish.

30 August 2023

\* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*

---

## CONTENTS

---

	<i>Page</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
I. <b>INTRODUCTION</b> .....	3
II. <b>PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS</b> .....	4
III. <b>PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS</b> .....	5
IV. <b>EGM</b> .....	6
V. <b>RECOMMENDATION</b> .....	7
<b>APPENDIX I – BIOGRAPHIES OF THE DIRECTOR CANDIDATES FOR THE SIXTH SESSION OF THE BOARD</b> .....	8
<b>APPENDIX II – BIOGRAPHIES OF THE INDEPENDENT SUPERVISOR AND SHAREHOLDER REPRESENTATIVE SUPERVISOR CANDIDATES FOR THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE</b> ..	14
<b>NOTICE OF EGM</b> .....	16

---

## DEFINITIONS

---

*In this circular, unless the context otherwise requires, the following expressions have the following meanings:*

“Articles of Association”	the articles of association of the Company
“Board”	the board of directors of the Company
“Company”	Sinopharm Group Co. Ltd., (國藥控股股份有限公司), a joint stock company incorporated under the laws of the PRC with limited liability and whose H shares are listed and traded on the Hong Kong Stock Exchange
“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are subscribed for and fully paid up in Renminbi by PRC nationals and/or PRC incorporated entities
“EGM”	the extraordinary general meeting of the Company to be convened at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC at 9:00 a.m. on Friday, 15 September 2023
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“H Share(s)”	overseas-listed foreign invested ordinary share(s) with a nominal value of RMB1.00 each in the share capital of the Company, which is/are listed and traded on the Hong Kong Stock Exchange
“Nomination Committee”	the nomination committee of the Board
“PRC”	the People’s Republic of China which, for the purpose of this circular, excludes Hong Kong, Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC

---

## DEFINITIONS

---

“Shareholder(s)”	the shareholder(s) of the Company
“Share(s)”	Domestic Share(s) and/ or H Share(s) of the Company
“Supervisor(s)”	the supervisor(s) of the Company
“Supervisory Committee”	the supervisory committee of the Company

---

## LETTER FROM THE BOARD

---



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

(A joint stock limited company incorporated in the People's Republic of China with limited liability  
and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

**Members of the Board:**

*Executive Directors:*

Mr. Yu Qingming (*Chairman*)  
Mr. Liu Yong

*Non-executive Directors:*

Mr. Chen Qiyu  
Mr. Hu Jianwei  
Mr. Ma Ping  
Mr. Deng Jindong  
Mr. Wang Kan  
Mr. Wen Deyong  
Mr. Li Dongjiu  
Ms. Feng Rongli

*Independent non-executive Directors:*

Mr. Chen Fangruo  
Mr. Li Peiyu  
Mr. Wu Tak Lung  
Mr. Yu Weifeng  
Mr. Shi Shenghao

*To the Shareholders*

Dear Sir or Madam,

- (1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS;  
(2) PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS; AND  
(3) NOTICE OF EGM**

### I. INTRODUCTION

References are made to the announcement of the Company dated 25 August 2023, in relation to (among others) proposed re-election and appointment of Directors and proposed re-election and appointment of Supervisors.

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

---

## LETTER FROM THE BOARD

---

The purpose of this circular is to provide you with detailed information regarding, among others, (i) the proposed re-election and appointment of Directors; (ii) proposed re-election and appointment of Supervisors and (iii) a notice convening the EGM, to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the EGM.

### II. PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS

As the term of office of the fifth session of the Board will expire on 17 September 2023, the Board has passed relevant resolutions on 25 August 2023 to make recommendations on the Director candidates for the sixth session of the Board.

#### **Proposed Re-election and Appointment of Directors**

The Board proposed to re-elect Mr. Yu Qingming and Mr. Liu Yong as executive Directors of the sixth session of the Board; to re-elect Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli as non-executive Directors of the sixth session of the Board; and to re-elect Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao as independent non-executive Directors of the sixth session of the Board. Meanwhile, the Board also proposed to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board at such meeting.

In accordance with the Articles of Association, the above proposed re-election and appointment of Directors is subject to the approval by the Shareholders at the general meeting of the Company. Relevant proposals will be submitted to the EGM for the Shareholders' consideration and approval.

Upon the above proposed re-election and appointment of Directors of the sixth session of the Board being approved by the Shareholders, the Company will enter into a service contract with each of them. The term of office of each of them as a Director of the sixth session of the Board will be three years from the date of approval by the Shareholders. Pursuant to the Articles of Association, each of the above proposed re-elected and appointed Directors will be subject to retirement by rotation and re-election upon the expiry of his/her term of office. The remuneration of each of them for serving as an executive Director, non-executive Director or independent non-executive Director of the sixth session of the Board will be determined by the Board according to the authorisation granted by the Shareholders at the annual general meeting of the Company held on 15 June 2023 and in accordance with the Company's remuneration standard regarding Directors. At present, according to the Company's 2023 remuneration standard, the remuneration of independent non-executive Directors will be RMB350,000 per annum (before tax); non-executive Directors will not receive any remuneration from the Company; executive Directors will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement.

Biographies of the Director candidates for the sixth session of the Board are set out in Appendix I to this circular.

---

## LETTER FROM THE BOARD

---

### **Recommendation of the Nomination Committee**

The above proposed re-election and appointment was proposed by the Nomination Committee according to the nomination procedure for Directors of the Company and based on the needs of the Company and submitted to the Board for review after the consideration of the Director candidate's relevant qualification by the Nomination Committee, and then will be submitted by the Board to the EGM for final approval.

The examination procedures of the candidates for Directors are: (1) to collect, or require relevant department of the Company to collect the particulars of the occupation, education, designation, detailed work experience and all part-time jobs of the candidates and summarize the same in written materials; (2) to hold the Nomination Committee meetings to examine the qualifications of the candidates in accordance with the requirements applicable to a Director of the Company and to state the opinion and recommendations on appointments in the form of proposals; and (3) to carry out other relevant work arrangement according to decisions of or feedback from the Board.

Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao have all confirmed their compliance with the independence guidelines set out in Rule 3.13 of the Hong Kong Listing Rules. The Nomination Committee had assessed and reviewed the written confirmation of independence of each of Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao based on the independence criteria as set out in Rule 3.13 of the Hong Kong Listing Rules and is satisfied that each of them is independent in accordance with Rule 3.13 of the Hong Kong Listing Rules.

In addition, when considering the candidates of independent non-executive Directors for the sixth session of the Board, the Audit Committee and the Board has considered the independence confirmations of Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao and their skills, background, knowledge and experience. In particular, Mr. Chen Fangruo has extensive experience in strategic management, Mr. Li Peiyu has extensive experience in corporate management and macroeconomic research, Mr. Wu Tak Lung has extensive experience in finance, Mr. Yu Weifeng has extensive experience in law and Mr. Shi Shenghao has extensive experience in medical health industry, industry operation and investment. Their different education, background, professional experience and practice enable them to provide relevant valuable insights and contributions to the diversity of the Board.

### **III. PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS**

As the term of office of the fifth session of the Supervisory Committee will expire on 17 September 2023, the Supervisory Committee has passed relevant resolutions on 25 August 2023 to make recommendations on the shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee.

The Supervisory Committee proposed to re-elect Ms. Guan Xiaohui and Mr. Liu Zhengdong as independent Supervisors of the sixth session of the Supervisory Committee. Meanwhile, the Supervisory Committee resolved at such meeting to propose to appoint Mr. Guo Jinhong as the shareholder representative Supervisor of the sixth session of the Supervisory Committee.

---

## LETTER FROM THE BOARD

---

In accordance with the Articles of Association, the above proposed re-election and appointment of Supervisors are subject to the approval by the Shareholders at the general meeting of the Company and relevant proposals will be submitted to the EGM for the Shareholders' consideration and approval, while the employee representative Supervisors of the sixth session of the Supervisory Committee shall be elected democratically by the employees of the Company and is not subject to the Shareholders' approval.

Upon the above proposed re-election and appointment of independent Supervisors and shareholder representative Supervisors of the sixth session of the Supervisory Committee being approved by the Shareholders, the Company will enter into a service contract with each of them. The term of office of each of them as a Supervisor of the sixth session of the Supervisory Committee will be three years from the date of approval by the Shareholders. Pursuant to the Articles of Association, each of the above proposed re-elected and appointed Supervisors will be subject to retirement by rotation and re-election upon the expiry of his/her term of office. The remuneration of each of them for serving as a shareholder representative Supervisor and an independent Supervisor of the sixth session of the Supervisory Committee will be determined by the Supervisory Committee according to the authorisation granted by the Shareholders at the annual general meeting of the Company held on 15 June 2023 and with reference to their duties in the Company, the Company's performance and the prevailing market condition. At present, according to the Company's 2023 remuneration standard, the remuneration of Mr. Liu Zhengdong, an independent Supervisor, will be RMB350,000 per annum (before tax) and other Supervisors (excluding employee Supervisors) will not receive any remuneration from the Company.

Biographies of the shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee are set out in Appendix II to this circular.

#### IV. EGM

A notice convening the EGM to be held at 9:00 a.m. on Friday, 15 September 2023 at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC is set out at the end of this circular.

In accordance with the Articles of Association, for the purpose of holding the EGM, the register of members of the Company (the "**Register**") will be closed from Tuesday, 12 September 2023 to Friday, 15 September 2023 (both days inclusive) during which period no transfer of shares of the Company will be registered.

In order to be qualified to attend and vote at the EGM, for holders of H shares of the Company, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as practicable, and in any event no later than 4:30 p.m. on Monday, 11 September 2023.

The Shareholders whose names appear on the Register on Tuesday, 12 September 2023 are entitled to attend and vote at the EGM.

---

## LETTER FROM THE BOARD

---

A proxy form to be used at the EGM is also enclosed herein and published on the website of the Hong Kong Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)). Shareholders who intend to appoint a proxy to attend the EGM shall complete, sign and return the appropriate proxy form in accordance with the instructions printed thereon.

For holders of H Shares, the proxy form, and if the proxy form is signed by a person under a power of attorney or other authority on behalf of the appointor, a notarially certified copy of that power of attorney or other authority, must be delivered to the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not less than 24 hours before the time for holding the EGM or any adjournment thereof in order for such documents to be valid. For holders of Domestic Shares, the proxy form, and if the proxy form is signed by a person under a power of attorney or other authority on behalf of the appointor, a notarially certified copy of that power of attorney or other authority, must be delivered to the Board Office of the Company in the PRC at Room 1210, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, 200023, the PRC, not less than 24 hours before the time for holding the EGM or any adjournment thereof in order for such documents to be valid.

Pursuant to Rule 13.39(4) of the Hong Kong Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. The chairman of the meeting will therefore demand a poll for every resolution put to vote at the EGM in accordance with the Articles of Association. An announcement on the poll vote results will be made by the Company after the EGM in the manner prescribed under Rule 13.39(5) of the Hong Kong Listing Rules.

### V. RECOMMENDATION

The Directors consider that all of the aforesaid resolutions are in the interests of the Company and the Shareholders as a whole, and accordingly, recommend the Shareholders to vote in favor of the relevant resolutions to be proposed at the EGM.

Yours faithfully,  
By Order of the Board  
**Sinopharm Group Co. Ltd.**  
**Yu Qingming**  
*Chairman*

The biographies of the Director candidates for the sixth session of the Board are as follows:

**EXECUTIVE DIRECTORS**

**Mr. Yu Qingming**, aged 59, is the chairman, executive Director and the secretary of Party Committee of the Company. Mr. Yu has over 36 years of working experience in the pharmaceuticals industry, especially in the management of pharmaceuticals and medical devices, and holds the professional title of senior engineer. Mr. Yu graduated from the Party School of the Central Committee of C.P.C majoring in economic management with a master degree. From July 1987 to February 1997, Mr. Yu successively worked at Beijing Pharmaceutical Station of CNPGC, China Medical Instrument Corporation and State Pharmaceutical Administration; from February 1997 to August 2010, Mr. Yu successively held senior management positions in The United Laboratories International Holdings Limited and China Medical Instrument Corporation. Mr. Yu has taken senior management positions of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since August 2010. He currently serves as a director of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. Mr. Yu joined the Group since December 2018 and currently serves as secretary of Party Committee, chairman and executive Director of the Company. Mr. Yu currently serves as director and general manager of Sinopharm Industrial Investment Co., Ltd. (“**Sinopharm Investment**”). Mr. Yu is currently also a representative of the 14th National People’s Congress, a party representative of the 12th Party Congress of Shanghai, vice president of China Association for Medical Devices Industry, vice chairman of China Association of Medical Equipment, and chairman of Medical Device Manager 50 Forum (MD50) etc. He is appointed as part-time professor in various universities such as East China University of Science and Technology and Shanghai University of Medicine & Health Sciences.

**Mr. Liu Yong**, aged 54, is an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu has over 31 years of working experience, over 28 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a doctoral degree in social and administrative pharmacy from China Pharmaceutical University. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu joined the Group since July 1992. He worked at Shanghai Pharmaceutical Station, China National Pharmaceutical Group Shanghai Co., Ltd., Shanghai Guoda Drug Chain Store Co., Ltd. and Sinopharm Holding Shenyang Co., Ltd. Mr. Liu held senior management positions in the Company since January 2009, and is currently also an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu is currently a representative of the 16th People’s Congress of Shanghai, and also serves as the vice chairman of Shanghai Shyndec Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600420)(“**Shyndec Pharmaceutical**”), and served as a director of Sinopharm Investment, China National Medicines Corporation Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600511)(“**Sinopharm (CNMC LTD)**”), and China National Accord Medicines Corporation Ltd. (a company listed on the Shenzhen Stock Exchange, A share stock code: 000028 and B share stock code: 200028) (“**Sinopharm Accord**”) and takes senior management positions in a number of subsidiaries.

## NON-EXECUTIVE DIRECTORS

**Mr. Chen Qiyu**, aged 51, is a non-executive Director and vice chairman of the Company. Mr. Chen has nearly 30 years of working experience. He obtained a bachelor's degree in genetics from Fudan University in July 1993 and an executive master's degree in business administration from China Europe International Business School in September 2005. Mr. Chen has joined Fosun Pharma Group (namely Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**") and its holding subsidiaries/units, hereafter the same) since 1994, and is currently the executive director and joint chief executive officer of Fosun International Limited (a company listed on the Hong Kong Stock Exchange (stock code: 00656)) ("**Fosun International**"), the non-executive director of Fosun Pharma (a company listed on the Shanghai Stock Exchange (stock code: 600196) and the Hong Kong Stock Exchange (stock code: 02196)), non-executive director of Shanghai Henlius Biotech, Inc. (a company listed on the Hong Kong Stock Exchange (stock code: 02696)) ("**Henlius**"), and non-executive director of Gland Pharma Limited (a company listed on Bombay Stock Exchange and National Stock Exchange of India, stock code: GLAND and GLAND) ("**GLAND**"). Mr. Chen has joined the Company since January 2003, and served as the chief Supervisor and non-executive Director of the Company, and is currently the non-executive Director and vice chairman of the Company. Mr. Chen served as the co-chairman of New Frontier Health Corporation (a company delisted from the NYSE in January 2022) and a director of Beijing Sanyuan Food Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600429). Mr. Chen concurrently served as the deputy chairman of Sinopharm Investment. Mr. Chen is currently the chairman of China Medical Pharmaceutical Material Association, vice chairman of China Pharmaceutical Innovation and Research Development Association, honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the standing member of the 14th Shanghai Committee of the Chinese People's Political Consultative Conference and part-time vice chairman of Shanghai Federation of Industry and Commerce (General Chamber of Commerce).

**Mr. Hu Jianwei**, aged 49, is a non-executive Director of the Company. Mr. Hu worked at government agencies for a long time from July 1994 to November 2017. He has in-depth research on macroeconomic operation and management and is familiar with medical and health work. He has served as a member of Party Committee and deputy general manager of China National Pharmaceutical Group Co., Ltd. ("**CNPGC**") since December 2017, and general counsel since January 2019, mainly responsible for work such as strategic planning, branding, operation and legal affairs. Mr. Hu has served as a non-executive Director of the Company since he joined the Group in December 2018.

**Mr. Deng Jindong**, aged 59, is a non-executive Director of the Company. He has over 35 years of working experience, over 30 years of which is financial management experience. Mr. Deng obtained a master's degree in economics from Central Institute of Finance and Economics (currently known as Central University of Finance & Economics) in January 1991. He is a non-practising PRC certified public accountant. Mr. Deng previously worked at Economic Information Network Data Co., Ltd. and Taikang Life Insurance Co., Ltd. Mr. Deng joined CNPGC since October 2002, and successively served as the head of the finance department and the chief accountant, and has served as the vice general manager of CNPGC since May 2017. Mr. Deng is currently also the chairman of Sinopharm Investment.

**Mr. Wang Kan**, aged 38, is a non-executive Director of the Company. Mr. Wang obtained a master's degree of science in pharmacognosy from the School of Pharmaceutical Sciences of Peking University Health Science Center in July 2009. Mr. Wang successively worked at the planning development and industrial management department of China National Pharmaceutical Industry Corporation Ltd. and the investment management department and securities department of China National Biotec Group Co., Ltd. respectively from August 2009 to November 2014. Mr. Wang has worked for CNPGC since November 2014 and held positions of the officer assistant and the deputy officer of the investment management department. He has been serving as the officer of the investment management department and the deputy officer of policy study office of CNPGC since August 2021. Mr. Wang has been a non-executive Director of the Company since December 2022. At present, Mr. Wang also serves as the director of China National Biotec Group Co., Ltd., China Traditional Chinese Medicine Holdings Co. Limited (a company listed on the Hong Kong Stock Exchange, stock code: 00570), China National Corp. of Traditional and Herbal Medicine, Chongqing Taiji Industry (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600129) and Fresenius Kabi Huarui Pharmaceutical Co., Ltd.

**Mr. Wang Peng**, aged 40, is a certified public accountant, an international certified internal auditor and a certified management accountant in the United States. Mr. Wang obtained a master's degree of economics in international trade from Tianjin University of Finance and Economics in June 2008 and obtained a master's degree of business administration from Guanghua School of Management in Peking University in June 2022. Mr. Wang worked at Tianjin Branch of Deloitte Touche Tohmatsu Certified Public Accountants LLP, Tianjin Branch of Standard Chartered Bank (China) Limited and Vcanland Holdings Group Company Limited (永泰紅礪控股集團有限公司) respectively from July 2008 to October 2015. Mr. Wang successively served as the financial manager of Vcanbio Cell & Gene Engineering Co., Ltd. since October 2015 and the financial director of the company from August 2017 to April 2022. Mr. Wang has been serving as the officer of the finance department of CNPGC since May 2022. Mr. Wang has been serving as a Supervisor of the Company since December 2022. Mr. Wang has served as a director of Shanghai Shyndec Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600420) since November 2022 and a director of Sinopharm Group Finance Co., Ltd. (國藥集團財務有限公司) since April 2023.

**Mr. Wen Deyong**, aged 52, is a non-executive Director of the Company. Mr. Wen graduated from Donghua University and received a master's degree in business administration in December 2007. Mr. Wen joined Fosun Pharma Group in May 2002, and is currently the executive director and the chief executive officer (CEO) of Fosun Pharma, and non-executive director of Henlius. Mr. Wen worked at Chongqing Yaoyou Pharmaceutical Co., Ltd. and Chongqing Healthman Pharma Co., Ltd. from September 1995 to May 2016. Mr. Wen has served as the non-executive Director of the Company since September 2017. Mr. Wen is currently also the director of Sinopharm Investment and Sinopharm (CNMC LTD), and a supervisor of Sinopharm Accord. Mr. Wen was also the director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300452) and C.Q. Pharmaceutical Holding Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000950).

**Mr. Li Dongjiu**, aged 58, is a non-executive Director of the Company. Mr. Li has over 35 years of working experience in the pharmaceutical industry, over 30 years of which relates to management experience in the pharmaceutical and healthcare products industry. Mr. Li is a professor-level senior engineer. Mr. Li obtained a PhD degree of transportation planning and management from Wuhan University of Technology, and then

obtained an EMBA degree from China Europe International Business School. Mr. Li held senior management positions in North China Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600812) from July 1987 to December 2009. Mr. Li joined Fosun Pharma Group for the first time in December 2009 and successively served as the president of Shanghai Fosun Pharmaceutical Development Co., Ltd., the chairman of the Commercialisation and Consumer Products Management Committee of Fosun Pharmaceutical, the senior vice president of Fosun Pharmaceutical, and also served as the director of Nature's Sunshine Products Inc (a company listed on the NASDAQ, NASDAQ: NATR) from December 2009 to January 2018; and rejoined Fosun Pharma Group in March 2021 and is currently serving as the senior vice president of Fosun Pharma. Mr. Li served as a non-executive Director of the Company from October 2013 to January 2018 and served as a vice president and chief legal advisor of the Company from January 2018 to March 2021. Mr. Li once served as a director of Sinopharm (CNMC LTD) and Sinopharm Accord. Mr. Li has been a non-executive Director of the Company since June 2021.

**Ms. Feng Rongli**, aged 48, is a non-executive Director of the Company. Ms. Feng graduated from Shanghai University with a major in microcomputer application in July 1996 and obtained a master's degree in business administration from Columbia Southern University in February 2002. Ms. Feng has extensive experience in the field of human resources management. Ms. Feng held human resources management positions in Sealed Air Packaging (Shanghai) Co., Ltd. (希悅爾包裝(上海)有限公司), Grundfos Pumps (Shanghai) Co., Ltd. (格蘭富水泵(上海)有限公司), Emerson Electric (China) Holdings Co., Ltd. (艾默生電氣(中國)投資有限公司), Dow Chemical (China) Co., Ltd. (陶氏化學(中國)有限公司), Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司), and F. Hoffmann-La Roche AG from July 1996 to February 2015. Ms. Feng served as the deputy chief human resources officer of Shanghai Fosun High Technology (Group) Company Limited and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd. (上海復星創業投資管理有限公司) from July 2018 to April 2020. Ms. Feng joined Fosun Pharma Group since April 2020 and is currently serving as the senior vice president of Fosun Pharma. Ms. Feng currently serves as the chairman of the supervisory committee of Henlius and the non-executive director of Sisram Medical Ltd (a company listed on the Hong Kong Stock Exchange, stock code: 01696). Ms. Feng has served as the non-executive Director of the Company since June 2020.

#### INDEPENDENT NON-EXECUTIVE DIRECTORS

**Mr. Chen Fangruo**, aged 58, is an independent non-executive Director of the Company. Mr. Chen obtained a Master's Degree from the Moore School of Electrical Engineering, University of Pennsylvania in 1987. He then received his Ph.D. degree from the Wharton School at the University of Pennsylvania. Mr. Chen worked at Columbia Business School in 1992, successively serving as the Assistant Professor, Associate Professor, Lifetime Associate Professor and Full Professor. In 2005, he became the Lifetime Chair Professor. During the foregoing period, Mr. Chen acted as a distinguished visiting professor at Stanford School of Business, Cheung Kong Graduate School of Business, Chinese Academy of Sciences, Shanghai Jiao Tong University, Peking University, Tianjin University and other prestigious universities at home and abroad. Mr. Chen has served as the independent non-executive Director of the Company since December 2018. Mr. Chen is currently a "Guangqi" fund sponsored professor, the Dean of Antai College of Economics and Management, the Dean of the Industry Research Institute, the Dean of the BOC Institute of Technology & Finance and the Dean of the Shenzhen Research Institute of Shanghai Jiao Tong University. Since 2019, he has served concurrently as the vice chairman of the National MBA Education Instruction Committee and a

director of the AMBA & BGA's International Management Board. Currently, Mr. Chen also served as the independent director of Yunnan Jianzhijia Health-Chain Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 605266).

**Mr. Li Peiyu**, aged 60, is an independent non-executive Director of the Company. Mr. Li obtained a PhD of management in Management Science and Engineering from School of Economics and Management, Tsinghua University and a Master of Public Administration (MPA) from Harvard University in June 1998. Mr. Li has worked in the areas of economics, finance and management for more than 30 years. From July 1987 to September 2000, he held positions in the Development Research Center of the State Council. From September 2000 to December 2007, Mr. Li successively served as the deputy director of Henan Provincial Development Planning Committee and the mayor of Hebi City in Henan Province. From December 2007 to November 2020, Mr. Li successively served as director of alternative investment department of China Investment Corporation, inspector of the research office of the State Council, chairman of China Reinsurance (Group) Corporation, and managing director of Beijing Zhongyu Green Investment Management Co., Ltd., managing director of CASIC Investment Fund Management (Beijing) Limited Company (航天科工投資基金管理(北京)有限公司) and the partner of the Beijing Qiyuanhouji Investment Management Co., Ltd. (北京啟源厚積投資管理有限公司). Mr. Li served as the managing director of Lotus Lake Venture Capital Management (Beijing) Co., Ltd. (荷塘創業投資管理(北京)有限公司) from January 2022 to February 2023. Mr. Li has served as the independent non-executive Director of the Company since September 2020.

**Mr. Wu Tak Lung**, aged 58, is an independent non-executive Director of the Company. Mr. Wu received a bachelor's degree in Business Administration from the Hong Kong Baptist University and a master's degree in business administration jointly from the University of Manchester and the University of Wales, respectively. Mr. Wu currently serves as an independent non-executive director of Kam Hing International Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 2307), Henan Jinma Energy Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 6885) and Zhongguancun Science-Tech Leasing Co., Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1601). In the last three years, Mr. Wu was an independent non-executive director of China Machinery Engineering Corporation, Minth Group Limited and Sinomax Group Limited. Mr. Wu previously served as an independent non-executive director of Beijing Media Corporation Limited ("**Beijing Media**"). Details in relation to the criticism of the current and retired directors of Beijing Media by the Hong Kong Stock Exchange are set out in the announcements of the Hong Kong Stock Exchange and the Company dated 10 February 2022 and 14 February 2022, respectively. Mr. Wu had worked in Deloitte Touche Tohmatsu, an international accounting firm, for five years. Mr. Wu has served as an independent non-executive Director of the Company since September 2020. Mr. Wu is currently a member of Hong Kong Institute of Certified Public Accountants, a senior fellow member of Hong Kong Securities and Investment Institute, the Association of Chartered Certified Accountants, the Taxation Institute of Hong Kong, and The Hong Kong Chartered Governance Institute.

**Mr. Yu Weifeng**, aged 52, is an independent non-executive Director of the Company. Mr. Yu is a lawyer with more than 27 years of working experience as a practicing lawyer. Mr. Yu obtained a bachelor's degree in laws from Fudan University in June 1995 and then obtained a master's degree in business administration from China Europe International Business School. From July 1995 to December 1998, Mr. Yu served as a paralegal and lawyer in Shanghai Pu Dong International Law Office (now renamed as Shanghai Pu Dong

Law Office). Mr. Yu has served as a partner in Llinks Law Offices since December 1998, and served as a director thereof from January 2014 to June 2020. Mr. Yu currently serves as an independent director of Shenergy Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600642) and Shanghai M&G Stationery Inc. (a company listed on the Shanghai Stock Exchange, stock code: 603899). Mr. Yu served as an independent director of Deppon Logistics Co., Ltd. and an external director of Jiahua Chemicals Inc. and Shanghai Life Science & Technology Co., Ltd. Mr. Yu has served as the independent non-executive Director of the Company since September 2020. Currently, Mr. Yu is also the chairman of Foreign-related Legal Services Committee of the All China Lawyers Association, president of Shanghai Arbitration Association, a member of Shanghai Arbitration Commission, and an arbitrator of Shanghai Arbitration Commission, Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center) and other arbitration institution and a mediator of Shanghai Commercial Mediation Center.

**Mr. Shi Shenghao**, aged 55, is an independent non-executive Director of the Company. Mr. Shi graduated from Capital Normal University with a bachelor's degree and obtained an EMBA degree from China Europe International Business School. Mr. Shi has more than 30 years of experience in the medical and health industry. He has served as a senior executive and general manager in Greater China for a number of multinational medical companies, and has extensive experience in industry operation and mergers and acquisitions. Mr. Shi is currently the managing partner of Riverhead Capital Investment Management Co., Ltd. Mr. Shi was the managing director of Sinopharm Capital Shanghai Co., Ltd. (國藥資本上海有限公司). He successively served as the marketing and sales director of GE Healthcare, the general manager in Greater China of American Medtronic China Co., Ltd. (美敦力中國有限責任公司), the general manager for diabetes healthcare business in Greater China of Bayer Group and the general manager in Greater China of Dentsply Sirona. Mr. Shi has served as the independent non-executive Director of the Company since June 2023.

As at the latest practicable date of this circular (being 26 August 2023), Mr. Yu Qingming has an interest in 100,000 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong, same below) and Mr. Liu Yong has an interest in 59,009 H shares of the Company.

Save as disclosed above, none of the above Director candidates for the sixth session of the Board has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or has any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above Director candidates for the sixth session of the Board held any other position in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any information in relation to the re-election or appointment of the above Director candidates for the sixth session of the Board that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

---

## APPENDIX II BIOGRAPHIES OF THE INDEPENDENT SUPERVISOR AND SHAREHOLDER REPRESENTATIVE SUPERVISOR CANDIDATES FOR THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE

---

The biographies of the independent Supervisor and shareholder representative Supervisor candidates for the sixth session of the Supervisory Committee are as follows:

**Ms. Guan Xiaohui**, aged 52, is the chief Supervisor of the Company. Ms. Guan obtained a bachelor's degree in economics from Jiangxi University of Finance and Economics and obtained a master's degree in accounting for senior accountant from The Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as Chinese Certified Public Account (CPA) and a member of The Association of Chartered Certified Accountants (ACCA). Ms. Guan has joined Fosun Pharma Group since May 2000 and currently serves as an executive director and vice chairman of Fosun Pharma. Ms. Guan worked at Jiangxi Provincial Branch of the Industrial and Commercial Bank of China from July 1992 to May 2000. Ms. Guan served as the non-executive Director of the Company from March 2019 to March 2021 and also once served as a supervisor of Sinopharm Accord. Ms. Guan has served as the Supervisor and the chief Supervisor of the Company since June 2021, and currently also serves as the vice president of Fosun International, a non-executive director of Henlius and a supervisor of Sinopharm Industrial Investment Co., Ltd. Ms. Guan served as a non-executive director of GLAND from October 2020 to August 2022.

**Mr. Liu Zhengdong**, aged 53, is a Supervisor of the Company. Mr. Liu is a lawyer who has more than 29 years of working experience as a practising lawyer. Mr. Liu obtained a master's degree in laws from East China University of Political Science and Law. He served as an assistant prosecutor in Railway Transportation branch of Shanghai People's Procuratorate from July 1991 to June 1994. From June 1994 to October 1998, Mr. Liu worked at Shanghai Hongqiao Law Firm and has been serving as a lawyer. Mr. Liu worked at Shanghai Junyue Law Firm from October 1998 to February 2022, and served as director and chief partner successively. Mr. Liu has been working in Jun He Law Offices since February 2022 as a partner. Mr. Liu has served as the independent non-executive Director of the Company from September 2014 to September 2020 and has been a Supervisor of the Company since September 2020. Mr. Liu served as president of the Eighth Session of Shanghai Bar Association and was also honored as National Excellent Lawyer and Shanghai Excellent Non-litigation Lawyer. Currently, Mr. Liu serves as a deputy to the 16th People's Congress of Shanghai, the standing director of the National Lawyers Association, the president of Shanghai Bankruptcy Administrators Association (上海市破產管理人協會) and the vice president of Shanghai General Chamber of Commerce. Mr. Liu also serves as an arbitrator of China International Economic and Trade Arbitration Commission (CIETA), Shanghai International Economic and Trade Arbitration Commission (SHIAC) and Shanghai Arbitration Commission (SAC).

**Mr. Guo Jinhong**, aged 50, is a senior auditor. Mr. Guo received a master's degree in monetary and banking professional economics from Shanxi Institute of Finance and Economics in July 1999. Mr. Guo worked in the Audit Office from July 1999 to March 2019, and served as the general manager of the audit department of Huajin Holdings Group Co., Ltd. (華錦控股集團有限公司) and the general manager of the audit supervisory department of China Railway Construction Capital Holding Co., Ltd. from March 2019 to February 2022. Mr. Guo joined CNPGC in February 2022 and served as the deputy director of the audit department of CNPGC and has served as the director of the audit department of CNPGC since June 2023.

Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance

---

**APPENDIX II    BIOGRAPHIES OF THE INDEPENDENT SUPERVISOR AND SHAREHOLDER REPRESENTATIVE  
SUPERVISOR CANDIDATES FOR THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE**

---

(Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee held any other position in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any information in relation to the re-election or appointment of the above independent Supervisor and shareholder representative Supervisor candidates for the sixth session of the Supervisory Committee that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

---

## NOTICE OF EGM

---



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

(A joint stock limited company incorporated in the People's Republic of China with limited liability  
and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

### NOTICE OF EXTRAORDINARY GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that an extraordinary general meeting (the “EGM”) of Sinopharm Group Co. Ltd. (the “**Company**”) will be held at 9:00 a.m. on Friday, 15 September 2023 at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the People's Republic of China (the “**PRC**”), for the purpose of considering, and if thought fit, passing the following resolutions:

#### Ordinary Resolutions

1. To consider and approve (if thought fit) the re-election of Mr. Yu Qingming as an executive director of the sixth session of the board of the Company (the “**Board**”), and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2. To consider and approve (if thought fit) the re-election of Mr. Liu Yong as an executive director of the sixth session of the Board of the Company, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
3. To consider and approve (if thought fit) the re-election of Mr. Chen Qiyu as a non-executive director of the sixth session of the Board of the Company, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
4. To consider and approve (if thought fit) the re-election of Mr. Hu Jianwei as a non-executive director of the sixth session of the Board of the Company, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

---

## NOTICE OF EGM

---

5. To consider and approve (if thought fit) the re-election of Mr. Deng Jindong as a non-executive director of the sixth session of the Board of the Company, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
6. To consider and approve (if thought fit) the re-election of Mr. Wang Kan as a non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
7. To consider and approve (if thought fit) the appointment of Mr. Wang Peng as a non-executive Director of the sixth session of the Board, to authorize the Board to determine his remuneration, and to authorize the chairman of the Board or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
8. To consider and approve (if thought fit) the re-election of Mr. Wen Deyong as a non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
9. To consider and approve (if thought fit) the re-election of Mr. Li Dongjiu as a non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
10. To consider and approve (if thought fit) the re-election of Ms. Feng Rongli as a non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
11. To consider and approve (if thought fit) the re-election of Mr. Chen Fangruo as an independent non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
12. To consider and approve (if thought fit) the re-election of Mr. Li Peiyu as an independent non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
13. To consider and approve (if thought fit) the re-election of Mr. Wu Tak Lung as an independent non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.

---

## NOTICE OF EGM

---

14. To consider and approve (if thought fit) the re-election of Mr. Yu Weifeng as an independent non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
15. To consider and approve (if thought fit) the re-election of Mr. Shi Shenghao as an independent non-executive director of the sixth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
16. To consider and approve (if thought fit) the re-election of Ms. Guan Xiaohui as an independent supervisor of the sixth session of the Supervisory Committee of the Company (the “**Supervisory Committee**”), and to authorize the chairman of the Board or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
17. To consider and approve (if thought fit) the re-election of Mr. Liu Zhengdong as an independent supervisor of the sixth session of the Supervisory Committee of the Company, and to authorize the chairman of the Board or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
18. To consider and approve (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative supervisor of the sixth session of the Supervisory Committee of the Company, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Yu Qingming**  
Chairman

Shanghai, the PRC  
30 August 2023

*As at the date of this notice, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*

*Notes:*

1. In accordance with the articles of association, for the purpose of holding the EGM, the register of members of the Company (the “Register of Members”) will be closed from Tuesday, 12 September 2023 to Friday, 15 September 2023 (both days inclusive), during which period no transfer of shares can be registered.

---

## NOTICE OF EGM

---

In order to be qualified to attend and vote at the EGM, for holders of H Shares, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, no later than 4:30 p.m. on Monday, 11 September 2023.

The Shareholders whose names appear on the Register of Members on Tuesday, 12 September 2023 are entitled to attend and vote at the EGM.

2. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a member of the Company.
3. The instrument appointing a proxy must be in writing under the hand of a shareholder or his attorney duly authorised in writing. If the shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same.
4. In order to be valid, the proxy form must be deposited, for the holders of H Shares, to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, or for the holders of Domestic Shares, to the Board Office of the Company in the PRC not less than 24 hours before the time appointed for holding the EGM or any adjourned thereof. If the proxy form is signed by a person under a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude Shareholders from attending and voting in person at the EGM or any adjourned meetings should you so wish.
5. Individual shareholders shall produce their identity documents and supporting documents in respect of the shares of the Company held when attending the EGM. If corporate shareholders appoint authorised representative to attend the EGM, the authorised representative shall produce his/her identity documents and a notarially certified copy of the relevant authorisation instrument signed by the board of directors or other authorised parties of the corporate shareholders or other notarially certified documents allowed by the Company. Proxies shall produce their identity documents and the proxy form signed by the shareholders or their attorney when attending the EGM.
6. The EGM is expected to take for less than half a day. Shareholders attending the EGM shall be responsible for their own travel and accommodation expenses.
7. Contact details of the Board Office of the Company in the PRC are as follows:

Address:	Room 1210, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, 200023, the PRC
Telephone No.:	(86 21) 2305 2147
Fax No.:	(86 21) 2305 2146